While the detailed mechanism by which FFX sensitizes AKT/mTORC1/MYC axis needs to be investigated, the targeting of FFX emerges as a promising therapeutic strategy for MYC-dependent cancers, offering a potential avenue for combating the otherwise elusive direct inhibition of MYC. This evidence concerns the gene AKT1 and cancer.